Abstracts tagged "Disease Activity"

Abstract Number: 2871 • 2018 ACR/ARHP Annual Meeting
Comprehensive Provider Judgement Is a Significant Determinant of Major Therapeutic Change in Patients with Moderate to Severe Rheumatoid Arthritis
Jacob R. Stever¹, Brian C. Sauer¹ and Grant W. Cannon², ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: We have previously reported an evaluation of 941 US Veterans in the Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry that 559 (59%)…
Abstract Number: 141 • 2018 ACR/ARHP Annual Meeting
Lymphocyte Activation Gene 3 Plasma Level Is Increased and Associated with Progression in Early Rheumatoid Arthritis
Janni Maria Pedersen^1,2,3, Aida Hansen⁴, Malene Hvid⁵, Kim Hørslev-Petersen⁶, Merete Lund Hetland⁷, Kristian Stengaard-Pedersen⁸, Mikkel Østergaard⁹, Bjarne Kuno Moeller¹⁰, Ellen-Margrethe Hauge¹¹, Peter Junker¹² and Bent Deleuran^1,2, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁴Biomedicine, Aarhus University, Aarhus, Denmark, ⁵Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁶King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁷University of Copenhagen, Copenhagen, Denmark, ⁸Department of Rheumatology, Aarhus University Hospital, Department of Clinical Medicine, Aarhus, Denmark, ⁹Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ¹⁰Department of Immunology, Aarhus University Hospital, Aarhus, Denmark, ¹¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Aarhus, Denmark, ¹²Department of Rheumatology C, Odense University Hospital, Odense, Denmark
Background/Purpose: Lymphocyte activation gene 3 (LAG3) resembles CD4 and is a key checkpoint molecule leading to downregulation of T cell proliferation and antigen presentation via…
Abstract Number: 509 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative
Kathy Cui¹, Mohammad Movahedi², Claire Bombardier³ and Bindee Kuriya^4,5,6, ¹Western University, London Health Sciences Centre, London, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Sinai Health System, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Rheumatoid arthritis increases the risk of cardiovascular disease (CVD). Less is known about the direct influence of CVD on RA outcomes, but higher comorbidity…
Abstract Number: 965 • 2018 ACR/ARHP Annual Meeting
Defining Cutoffs Corresponding to Low Levels of Disease Activity in Psoriatic Arthritis, Using the Patient-Reported Psoriatic Arthritis Impact of Disease Questionnaire (PsAID12). an Analysis of 436 Patients
Clémence Gorlier¹, Deborah Puyraimond-Zemmour¹, Ana-Maria Orbai², Laura C. Coates³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder^15,16, Inna Gaydukova¹⁷, Ennio Lubrano¹⁸, Pascal Richette¹⁹, M. Elaine Husni²⁰, Maarten de Wit²¹, Josef S. Smolen²² and Laure Gossec²³, ¹Sorbonne Université, PARIS, France, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Oxford, Oxford, United Kingdom, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ¹⁷North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁸Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁹Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ²⁰Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²¹Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²²Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²³Rhumatologie, Médecine Sorbonne Université, Pitié-Salpétrière Hospital, Paris, France
Background/Purpose: The Psoriatic Arthritis (PsA) Impact of Disease questionnaire (PsAID12) score allows an assessment of patient-important symptoms and life impact in PsA. It is provisionally…
Abstract Number: 1495 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy
Jeffrey Kaine¹, Alan J. Kivitz², Eduardo Mysler³, Noriko Iikuni⁴, Haiyun Fan⁵, Annette Diehl⁵, Jerome Paulissen⁶ and Christopher W Murray⁵, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Syneos Health, Raleigh, NC
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Strategy (NCT02187055) was a Phase 3b/4, 1-year, double-blind, triple-dummy, active comparator-controlled…
Abstract Number: 1701 • 2018 ACR/ARHP Annual Meeting
Lupus Low Disease Activity State: Predicting Organ Damage Accrual and Cardiovascular Risk in Patients with Systemic Lupus Erythematosus
Ruta Tesfamicael¹, Harrison Lam², Oria Lu², Ratushtar Kapadia¹, Caroline Siegel¹, Lori Sahakian¹, Jennifer M. Grossman^1,3 and Maureen A. McMahon^1,4, ¹University of California, Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los angeles, CA, ³Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease that can cause multisystem inflammation and damage. There are currently no widely agreed upon targets for…
Abstract Number: 2180 • 2018 ACR/ARHP Annual Meeting
Differences in Longitudinal Disease Activity Measures between Research Cohort and Non-Cohort Participants with Rheumatoid Arthritis Using Electronic Health Record Data
Milena Gianfrancesco¹, Laura Trupin¹, Charles McCulloch², Stephen Shiboski³, Jonathan Graf⁴, Gabriela Schmajuk⁵ and Jinoos Yazdany⁶, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ³Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, ⁵San Francisco VA Medical Center, San Francisco, CA, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: Research using electronic health records (EHR) may offer advantages over traditional observational studies, including lower costs and greater generalizability to a broader patient population;…
Abstract Number: 2532 • 2018 ACR/ARHP Annual Meeting
The Efficacy and Drug Survival of the Biosimilar Infliximab (CT–P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry
Sadettin Uslu¹, Gerçek Can¹, Soner Senel², Ediz Dalkiliç³, Nevsun Inanc⁴, Servet Akar⁵, Sinem Burcu Kocaer¹, Merih Birlik¹, Sedat Capar⁶, Nurullah Akkoc⁷ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ³Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁴Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁵Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁶Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ⁷Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: Biosimilar infliximab (CT-P13) has been used to treat patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Turkey since 2013.The…
Abstract Number: 2887 • 2018 ACR/ARHP Annual Meeting
Chronic Pain and Assessment of Pain Sensitivity in Patients with Established Axial Spondyloarthritis – a Cross-Sectional Study
Elisabeth Mogard¹, Tor Olofsson², Stefan Bergman³, Ann Bremander⁴, Lars Erik Kristensen⁵, Jack Kvistgaard Olsen⁶, Johan K Wallman⁷ and Elisabet Lindqvist⁸, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Faculty of Medicine and Skåne University Hospital, Lund, Sweden, ²Lund University, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ³University of Gothenburg, Gothenburg, Sweden, ⁴Spenshult Research and Development Center, Halmstad, Sweden, ⁵Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, The Parker Institute, Copenhagen, Denmark, ⁶Department of Rheumatology, Copenhagen University Hospital, Fredriksberg and Bispebjerg, The Parker Institute, Copenhagen, Denmark, ⁷Department of Clincial Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ⁸Department of Clinical Sciences Lund,Section of Rheumatology, Lund University, Faculty of Medicine and Skåne University Hospital, Lund, Sweden
Background/Purpose: Pain remains a common and debilitating symptom in arthritis, despite good options to treat inflammation. In axial spondyloarthritis (axSpA), data on chronic pain remain…
Abstract Number: 210 • 2018 ACR/ARHP Annual Meeting
Changes in Alcohol Use in Patients with Rheumatoid Arthritis: Associations with Disease Activity, Health Status, and Mortality
Joshua Baker¹, Harlan Sayles², Bryant R. England³, Ted R. Mikuls⁴ and Kaleb Michaud⁵, ¹Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁵Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Prior studies observed better disease control, quality of life, and physical function among patients with rheumatoid arthritis (RA) who drink alcohol. These studies may…
Abstract Number: 533 • 2018 ACR/ARHP Annual Meeting
Association between Inflammation and Changes in Kidney Function in Patients with Early Rheumatoid Arthritis
Ganna Prytkova¹, Dmytro Rekalov² and Daryna Nikitina¹, ¹Rheumatology, Zaporizhzhya Regional Clinical Hospital, Zaporizhzhya, Ukraine, ²Department of Internal Diseases, Zaporizhzhya Regional Clinical Hospital, Zaporizhzhya, Ukraine
Background/Purpose: One of the most severe visceral manifestations of RA is nephropathy. The key symptoms of renal dysfunction (RD) are microalbuminuria (MA), β-2-microglobulinuria (β-2M), reduced…
Abstract Number: 1060 • 2018 ACR/ARHP Annual Meeting
Variation in the Synovial Fluid Metabolome According to Disease Activity in Rheumatoid Arthritis
Joong Kyong Ahn¹, Jiwon Hwang², Jaejoon Lee³, Eun-Mi Koh³ and Hoon-Suk Cha³, ¹Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Internal Medicine, National Police Hospital, Seoul, Korea, Republic of (South), ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease characterized by persistent inflammation and joint damage with a heterogeneous course and different pathogenic mechanisms. Metabolomics,…
Abstract Number: 1500 • 2018 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients
Nadia MT Roodenrijs¹, Maria JH de Hair¹, Gill Wheater², Mohsen Elshahaly³, Janneke Tekstra¹, Y.K. Onno Teng⁴, Floris PJG Lafeber¹, Ching Chang Hwang⁵, Xinyu Liu⁶, Eric H. Sasso⁵ and Jacob van Laar¹, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Department of Biochemistry, The James Cook University Hospital, Middlesbrough, UK, Middlesbrough, United Kingdom, ³Department of Rheumatology & Rehabilitation, Suez Canal University, Ismailia, Egypt, Ismailia, Egypt, ⁴Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁵Crescendo Bioscience, San Francisco, CA, USA, South San Francisco, CA, ⁶Crescendo Bioscience, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: A multi-biomarker disease activity (MBDA) score was developed to objectively measure disease activity for patients with rheumatoid arthritis (RA).1 The MBDA score is calculated…
Abstract Number: 1732 • 2018 ACR/ARHP Annual Meeting
Alterations of Body Composition in Patients with Systemic Scleroderma Are Associated with Disease Activity, Physical Activity and Serum Levels of Inflammatory Cytokines
Sabina Oreska^1,2, Maja Spiritovic^1,3, Petr Cesak⁴, Michal Cesak⁵, Hana Storkanova^1,2, Hana Smucrova¹, Barbora Hermankova^1,3, Barbora Sumova^1,2, Olga Ruzickova^1,6, Herman F Mann^1,7, Karel Pavelka^1,2, Ladislav Šenolt^1,2, Jiri Vencovsky^1,8, Radim Becvar^1,2 and Michal Tomcik^1,2, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Body Composition Laboratory, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁸Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Fibrosis of the skin and visceral organs, especially digestive tract, and musculoskeletal involvement in systemic sclerosis (SSc) can have a negative impact on body…
Abstract Number: 2188 • 2018 ACR/ARHP Annual Meeting
Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
Filip van Den Bosch¹, Andrew Ostor², Patrick Zueger³, Meijing Wu³, Ivan Lagunes Galindo³ and Siegfried Wassenberg⁴, ¹Ghent University Hospital, Ghent, Belgium, ²Cabrini Medical Center, Melbourne, Australia, ³AbbVie Inc., North Chicago, IL, ⁴Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Patients (pts) receiving adalimumab for RA or other indications are offered participation in the AbbVie pt support program (PSP). This analysis assessed clinical outcomes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].